Clinical trials: Depressive; Behavioral Disorder
Major Depressive Disorder
Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder
This study will evaluate the long-term safety and tolerability of escitalopram (Lexapro) in children 7 to 11 years of age with major depressive disorder (MDD).
- Trial name
- NCT01198795
- Testing
- Escitalopram
- Where
- 16 sites in United States
- Volunteers
- 162 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
This is a Double-blind Study Evaluating Desvenlafaxine Succinate (DVS SR) Sustained Release vs Placebo in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder (MDD).
- Trial name
- NCT01372150
- Testing
- desvenlafaxine succinate sustained release, fluoxetine
- Where
- 43 sites in United States, Mexico
- Volunteers
- 340 people
- Sponsor
- Pfizer
Major Depressive Disorder
Focal Electroconvulsive Therapy for Depression
This pilot, open label investigation evaluates the safety and efficacy of a new form of electroconvulsive therapy (ECT). Both the efficacy and adverse cognitive effects of ECT are highly contingent on the intracerebral current…
- Trial name
- FEAST (NCT01589315)
- Testing
- focal ECT
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Medical University of South Carolina
Major Depressive Disorder, Posttraumatic Stress Disorder
Comparing Group Therapies for Veterans With Depression and PTSD
Cognitive behavioral therapy (CBT) is a brief, efficient, and effective psychotherapy for individuals with depressive and PTSD. However, CBT is largely underutilized within Veteran Affairs Medical Centers (VAMCs) due to the cost…
- Trial name
- NCT03979040
- Testing
- Group Transdiagnostic Behavior Therapy, Group Disorder-Specific Therapy (G-DSTs)
- Where
- United States
- Volunteers
- 294 people
- Sponsor
- VA Office of Research and Development
Major Depressive Disorder
Stimulant Enhancement of Well-Being Therapy for Depression
This study aims to identify a novel enhancement strategy for residual symptoms of major depressive disorder (MDD) Dopamine (DA) has been viewed as a "pleasure neurotransmitter" for over 30 years.
- Trial name
- NCT01478113
- Testing
- Amphetamine/dextroamphetamine, Well-being therapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
The primary objective of this study is to assess whether LY2216684 12 milligrams (mg) or 18 mg flexible dose once daily is superior to placebo once daily in the adjunctive treatment of participants with major depressive disorder…
- Trial name
- NCT01185340
- Testing
- LY2216684, SSRI
- Where
- 49 sites in United States, Australia and 5 more
- Volunteers
- 1,056 people
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major
A Study of Psilocybin for Major Depressive Disorder (MDD)
One hundred participants, ages 21 to 65, who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for major depressive disorder (MDD) will be stratified by study site and randomized with a 1-to-1 allocation…
- Trial name
- NCT03866174
- Testing
- Psilocybin, Niacin, Set and Setting (SaS) Protocol
- Where
- 11 sites in United States
- Volunteers
- 347 people
- Sponsor
- Usona Institute
Major Depressive Disorder
PET Biomarkers in Treatment Resistant Depression
The primary objectives of the study are to test whether brain Mono Amine Oxidase-A (MAO-A) levels are elevated in patients with treatment-resistant major depression, and to explore whether MAO-A brain levels predict treatment…
- Trial name
- NCT01031810
- Testing
- tranylcypromine
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Perinatal Depression, Post Partum Depression
Characterizing the Neural Substrates of Irritability in Women: an Experimental Neuroendocrine Model
The proposed study involves experimentally manipulating reproductive hormones in nonpregnant, euthymic women to create a scaled down version of the changes that occur during pregnancy and the postpartum period.
- Conditions
- Perinatal Depression, Post Partum Depression, Depression, Postpartum, Depression
- Trial name
- NCT04051320
- Testing
- Leuprolide Acetate 3.75 MG/ML, Estradiol 2 Mg tablet, Micronized progesterone
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Depression, Anxiety
Cognitive Behavioral Immersion: A Randomized Control Trial of Peer-Based Coaching in the Metaverse
This study will test a new cognitive-behavioral skills training program (CBI) delivered in the metaverse. Although initial evidence suggested CBI was feasible for individuals experiencing depression or anxiety, CBI's…
- Trial name
- NCT06418997
- Testing
- CBI
- Where
- United States
- Volunteers
- 306 people
- Sponsor
- University of Southern California
Perimenopausal Disorder, Depression
Effects of a Tissue Selective Estrogen Complex (TSEC) on Depression and the Neural Reward System in the Perimenopause"
Using neuroimaging, the investigator will study the effects of estrogen on mood and brain function in perimenopausal women with depression.
- Trial name
- Duavee (NCT03740009)
- Testing
- Bazedoxifene/Conjugated Estrogen
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Major Depressive Disorder
The Effectiveness of rTMS in Depressed VA Patients
The purpose of this multi-site trial is to determine if repetitive Transcranial Magnetic Stimulation (rTMS) helps people with depression who have not been helped by medications or who have not been helped enough by medications.
- Trial name
- NCT01191333
- Testing
- rTMS
- Where
- 9 sites in United States
- Volunteers
- 164 people
- Sponsor
- VA Office of Research and Development
Major Depressive Disorder
The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder
Depression affects approximately 2.5% of children and 8% of adolescents. Escitalopram is the S-enantiomer of citalopram. Both escitalopram and citalopram are selective serotonin reuptake inhibitors (SSRIs) and are used to treat…
- Trial name
- NCT00107120
- Testing
- Escitalopram
- Where
- 28 sites in United States
- Volunteers
- 312 people
- Sponsor
- Forest Laboratories
Treatment Resistant Depression, Major Depressive Disorder
Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)
This study is a multi-center, open-label trial to evaluate the long-term safety and efficacy of AXS-05 in subjects with major depressive disorder with prior treatment failures
- Trial name
- NCT04634669
- Testing
- AXS-05 (dextromethorphan-bupropion)
- Where
- 20 sites in United States
- Volunteers
- 181 people
- Sponsor
- Axsome Therapeutics, Inc.
Acute Coronary Syndrome, Depression
MBCT Delivered Via Group Videoconferencing for ACS Syndrome Patients With Depressive Symptoms
Brief Summary: The aim of this study is to explore the initial feasibility and acceptability of (a) Mindfulness-Based Cognitive Therapy (MBCT) adapted for ACS patients; (b) the group videoconferencing delivery medium; and (c)…
- Conditions
- Acute Coronary Syndrome, Depression, Myocardial Infarction, Unstable Angina
- Trial name
- NCT04231097
- Testing
- MBCT intervention for ACS patients
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Augmenting Single-session Behavioral Activation (BA) With Delta-beta Transcranial Alternating Current Stimulation (tACS) for the Treatment of Depression
Investigating whether delta-beta cross-frequency transcranial alternating current stimulation can augment the effects of a single session of behavioral activation in participants with major depressive disorder.
- Trial name
- ABBA (NCT05693922)
- Testing
- Delta-beta cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC, Single-session behavioral activation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of North Carolina, Chapel Hill
Major Depressive Disorder
Efficacy and Safety Study of a Combination Product [Drug:BCI-024 (Buspirone) and Drug:BCI-049 (Melatonin)] to Treat Major Depressive Disorder (MDD)
The primary objective of this study are to evaluate the synergistic effect of a combination product, consisting of drug BCI-024 (buspirone) and drug BCI-049 (melatonin), in reducing symptoms of depression in patients with Major…
- Trial name
- NCT00705003
- Testing
- BCI-024: over-encapsulated Buspirone tablet 15 mg QD and BCI-049: over-encapsulated Melatonin tablet 3 mg QD, BCI-024 (Buspirone)
- Where
- 9 sites in United States
- Volunteers
- 142 people
- Sponsor
- Massachusetts General Hospital
Depression
Reclaim Deep Brain Stimulation Clinical Study for Treatment-Resistant Depression
Medtronic, Inc. sponsored an investigational study of the Reclaim™ Deep Brain Stimulation (DBS) System in people that have treatment-resistant depression.
- Trial name
- NCT00837486
- Testing
- Reclaim™ DBS System
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- MedtronicNeuro
Mental Health Issue, Anxiety
Clinical Investigation of Wysa
Mental health concerns are a large burden for individuals, healthcare systems, and the economy. Over a million people are referred to UK mental health services each year, but more than half only receive one session of…
- Conditions
- Mental Health Issue, Anxiety, Depressive Symptoms
- Trial name
- NCT05533190
- Testing
- Wysa AI chatbot mental health app
- Where
- 2 sites in United Kingdom
- Volunteers
- 76 people
- Sponsor
- University of Plymouth
Major Depressive Disorder
Therapist-Guided Smartphone-Delivered CBT for MDD
We are testing a smartphone app that provides therapy for depression. Participants will also receive short weekly virtual appointments with a therapist.
- Trial name
- NCT05386329
- Testing
- Mindset: Therapist-guided smartphone-delivered CBT
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Massachusetts General Hospital